Friday, 16 October 2026European Markets

DGB GROUP N.V. Stock Was 11.14% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with DGB GROUP N.V. (DGB.AS) jumping 11.14% to €0.78 on Wednesday, after two successive sessions in a row of gains. AEX-Index slid 0.38% to €923.13, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

DGB GROUP N.V.'s last close was €0.70, 10.26% under its 52-week high of €0.78.

About DGB GROUP N.V.

DGB Group N.V. invests in, develops, and manages carbon credits and biodiversity projects for businesses and governments in the Netherlands and internationally. The company offers nature-based solutions comprising removing or avoiding carbon emissions, tackling social, and environmental challenges; manages projects that focuses on ecosystem restoration, habitat conservation, and biodiversity enrichment; and undertakes plastic projects, which consists of removing and recycling plastic, waste reduction, and environmental conservation works, as well as carbon offsetting projects for reducing carbon footprint of companies. It also provides ESG reporting and tree integration services. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 and is based in Haarlemmermeer, the Netherlands.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.73%.

Volatility

DGB GROUP N.V.'s last week, last month's, and last quarter's current intraday variation average was 0.98%, 0.34%, and 3.34%.

DGB GROUP N.V.'s highest amplitude of average volatility was 1.78% (last week), 3.17% (last month), and 3.34% (last quarter).

More news about DGB GROUP N.V. (DGB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com